UCSD researchers discover variants of natural tumor suppressorApril 10, 2007Building on their 2005 discovery of an enzyme that is a natural tumor suppressor, researchers at the University of California, San Diego (UCSD) School of Medicine have now identified two variants of that enzyme which could provide new targets for therapies to treat diabetes, heart and neurological disease. The findings, by Alexandra C. Newton, Ph.D., UCSD professor of pharmacology, and colleagues are published in the current edition of the journal Molecular Cell. Previous research by Newton's lab, also published in Molecular Cell, described the discovery of an enzyme they named PH domain Leucine-rich repeat Protein Phosphatase (PHLPP, pronounced "flip") that turns off signaling of the Akt/protein kinase B, a protein which controls cell growth, proliferation and survival. The new work describes a second family member, PHLPP2, which also inactivates Akt, inhibiting the cell cycle progression and promoting cell death. However, PHLPP1 and PHLPP2 control three different disease pathways. While both are important in cancer, PHLPP 1 impacts an important pathway in diabetes and PHLPP2 could be useful in fighting heart and neurological disease.
"We first discovered that PHLPP controls Akt, which is the driver on the pathway to tumor growth," said Newton. "PHLPP is like a brake that, when on, slows the driver but when 'off' allows the driver to move. In cancer, we want the driver to brake, to prevent cell proliferation leading to tumor growth. But in diabetes, heart or neurological disease, where we want to promote cell growth and survival, we don't want to slow the driver down." The researchers have now found that PHLPP1 controls the driver along one pathway - Akt2, which is more closely involved in maintaining a constant level of glucose in the bloodstream. Therapies directed at inhibiting PHLPP1 could be used to treat diabetes; in essence, removing the 'brake' and allowing Akt2 to be more functional and allow better insulin regulation. PHLPP2, on the other hand, controls the driver on Akt1, the path involved with cell survival. Therapies directed at releasing the brake on this driver would allow cells involved in heart or neurological diseases to better survive. "Both PHLPP variants are important in cancer; the loss of a brake to any of the three Akt pathways sends 'go, go, go' signals that promote the survival of tumor cells," said first author John Brognard. UCSD researchers had previously discovered that Akt is hyperactivated, or elevated, in most cancers and PHLPP provides a mechanism to reverse this activation. University of California-San Diego | |||||||||||||||||||||
|
Related Tumor Suppressor Current Events and Tumor Suppressor News Articles Science teams at Cold Spring Harbor Laboratory identify 13 new tumor-suppressor genes in liver cancer Over the years, hunting for cancer-related genes and understanding how they work has been an important, although time-consuming, exercise. At Cold Spring Harbor Laboratory (CSHL), five different research groups have now combined their expertise to speed up the rate of discovering cancer-related genes and validating their function in living animals. New journal shows half-broken gene is enough to cause cancer Tumour suppressor genes do not necessarily require both alleles to be knocked out before disease phenotypes are expressed. Research published in BioMed Central's new open access journal PathoGenetics reveals that only one allele of SMAD4 has to be damaged to put a person at risk of pancreatic and colorectal cancer. UC Davis researchers discover a key to aggressive breast cancer In trying to find out why HER2-positive breast cancer can be more aggressive than other forms of the disease, UC Davis Cancer Center researchers have surprisingly discovered that HER2 itself is the culprit. By shutting down its own regulator gene, HER2 creates a permissive environment for tumor growth. Novel marker of colon cancer Colon cancer ranks second of all gastrointestinal malignant tumors, it is one of the leading causes of cancer-related deaths worldwide. Novel genetic screens provide panoramic views of cellular systems Despite the rise of systems biology, many geneticists continue to probe genes in isolation. They even use cutting-edge RNA interference (RNAi) technology to knock down one gene at a time. This approach often yields a narrow view of cellular systems. Scientists identify genes capable of regulating stem cell function Scientists from The Forsyth Institute, Boston, MA, and the Howard Hughes Medical Institute at the University of Utah School of Medicine have developed a new system in which to study known mammalian adult stem cell disorders. '1-hit' event provides new opportunity for colon cancer prevention, say Fox Chase researchers More than 30 years ago, Alfred Knudson Jr., M.D., Ph.D., revolutionized the field of cancer genetics by showing that a person must lose both their paternal and maternal copies of a particular class of cancer-inhibiting genes, called tumor-suppressor genes, in order to develop cancer. Early stage colon cancer characterized by inactivation of gatekeeper gene The absence or inactivation of the RUNX3 gatekeeper gene paves the way for the growth and development of colon cancer, Singapore scientists report in the Sept. issue of the journal Cancer Cell. Previous studies have shown that RUNX3 plays a role in gastric, breast, lung and bladder cancers. International team reveals first prognosticator of survival in aggressive cancer The tumor suppressor gene pRb2/p130 may provide the first independent prognostic biomarker in cases of soft tissue sarcoma (STS). Why a common treatment for prostate cancer ultimately fails Some of the drugs given to many men during their fight against prostate cancer can actually spur some cancer cells to grow, researchers have found. The findings were published online this week in a pair of papers in the Proceedings of the National Academy of Sciences. More Tumor Suppressor Current Events and Tumor Suppressor News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||